
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is well-positioned to revolutionize the practice of data-driven medicine with its innovative platform and strong partnerships. Their projected growth and plans for achieving profitability demonstrate their potential for long-term success in the healthcare technology industry.
Bears say
Sophia Genetics is currently expanding its work with Memorial Sloan Kettering to form a joint venture and Precision Medicine Hub, which has the potential to enhance its precision oncology capabilities. However, Sophia Genetics has not finalized the JV's details or terms, and its current financials show a decline in revenue per analysis, which may be impacted by headwinds with biopharmaceutical customers. Additionally, Sophia Genetics also faces stiff competition from established players like Guardant Health and Tempus AI, Inc, with the latter having incurred significant losses and debt on its balance sheet.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares